Search | Clinical Trials Finder

Conditions: Glioblastoma
Interventions: Enzastaurin Hydrochloride, Placebo, Temozolomide, Radiotherapy; Drug · Other · Radiation
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more

Conditions: Acute Treatment of Migraine
Interventions: Rimegepant; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 21
States / cities: Canoga Park, California • Fresno, California • Los Angeles, California + 16 more

Conditions: Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cystoscopy, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Pembrolizumab, Transurethral Resection of Bladder Tumor; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 381
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 257 more

Conditions: Prostate Cancer (Adenocarcinoma)
Interventions: Abiraterone, Enzalutamide, Apalutamide, Darolutamide (BAY 1841788), Docetaxel, ADT; Drug
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 374
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 272 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: FOCAL+, VR-FOCAL+; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 16 Years to 19 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: ADHD
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 7 Years to 110 Years
Enrollment: 3,481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2020
U.S. locations: 2
States / cities: Orange, California • Bethesda, Maryland

Conditions: Asthma
Interventions: GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS); Biological · Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 1,717 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 119
States / cities: Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more

Conditions: Asthma
Interventions: CSJ117, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 21
States / cities: Bakersfield, California • Huntington Beach, California • Los Angeles, California + 16 more

Conditions: Hearing Loss, Attention Deficit and Disruptive Behavior Disorders, Parenting
Interventions: Family Check Up Behavioral Parenting Training Program (BPT), Behavioral Placebo; Behavioral
Lead sponsor: University of Kentucky; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Lexington, Kentucky • Louisville, Kentucky

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions: Placebo, 100mg SPN-812, 200mg SPN-812, 300mg SPN-812, 400mg SPN-812; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Maitland, Florida

Conditions: Mild Traumatic Brain Injury
Interventions: VIDAS® TBI Test [GFAP and UCH-L1 assays]; Diagnostic Test
Lead sponsor: BioMérieux; Industry
Eligibility: 18 Years and older
Enrollment: 903 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Orlando, Florida • Detroit, Michigan • Rochester, Minnesota + 2 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Autism, Autism Spectrum Disorder
Interventions: Adderall XR (mixed salts amphetamine), Placebo; Drug
Lead sponsor: Gagan Joshi; Other
Eligibility: 8 Years to 18 Years
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes Mellitus
Interventions: Tesaglitazar 0.5, Insulin at least 30 units/day; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tuscson, Arizona + 68 more

Conditions: Treatment-resistant Schizophrenia
Interventions: Evenamide 15 mg bid, Placebo; Drug
Lead sponsor: Newron Pharmaceuticals SPA; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Miami, Florida • Atlanta, Georgia + 2 more

Conditions: Colorectal Cancer, CRC
Interventions: Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 2
States / cities: Richmond, Virginia

Conditions: ADHD
Interventions: Neurofeedback, Sham Neurofeedback; Other
Lead sponsor: University of North Carolina, Wilmington; Other
Eligibility: 18 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Healthy
Interventions: NeuroQ; Dietary Supplement
Lead sponsor: LifeSeasons Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Studio City, California • Flower Mound, Texas

Conditions: Alzheimer's Disease
Interventions: AGN-242071, Placebo, Donepezil, Memantine; Drug
Lead sponsor: Allergan; Industry
Eligibility: 55 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 6
States / cities: Costa Mesa, California • Irvine, California • Lemon Grove, California + 2 more

Conditions: Conduct Disorder
Interventions: Family-Based Preventive Intervention; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 33 Months to 63 Months
Enrollment: 1,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1997
U.S. locations: 1
States / cities: New York, New York

Conditions: Secondary Amenorrhea
Interventions: PROMETRIUM® 300 mg, PROMETRIUM® 400 mg; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 42
States / cities: Mobile, Alabama • Montgomery, Alabama • Tucson, Arizona + 36 more

Conditions: Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Stroke, Hypercholesterolemia
Interventions: lerodalcibep, Placebo; Drug · Other
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Cincinnati, Ohio

Conditions: ADHD, Perinatal, Behavioral Intervention
Interventions: MomMA Intervention, Treatment as Usual (TAU); Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Tafasitamab, Tafasitamab plus lenalidomide; Drug
Lead sponsor: MorphoSys AG; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 23
States / cities: Tucson, Arizona • Anaheim, California • Duarte, California + 20 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: galantamine; Drug
Lead sponsor: North Suffolk Mental Health Association; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Improving ADHD Teen Driving - Virtual Reality

Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

Assessing and Addressing Behaviors in Children With Hearing Loss

Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

VIDAS® TBI Real Life Performance in Subjects With Mild Traumatic Brain Injury (mTBI)

The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine

GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer

An Evaluation of Neurofeedback Efficacy in Adults With ADHD

A Study Investigating the Effectiveness of a LifeSeasons NeuroQ Supplement With Lifestyle Changes to Improve Cognitive Function in Healthy Adults Who Have One or More Risk Factors for Cognitive Decline

A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

Early Prevention of Conduct Problems

Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion

Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

Expectant Moms Managing Attention-Deficit/ Hyperactivity Disorder

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Galantamine for Cognition in People With Schizophrenia